PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/08/23
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 10/12/23
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of NeurologyGlobeNewsWire • 09/27/23
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1GlobeNewsWire • 09/06/23
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical ConferencesGlobeNewsWire • 09/06/23
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/01/23
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/08/23
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1GlobeNewsWire • 06/13/23
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire • 05/30/23
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 05/18/23
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/11/23
PepGen to Participate in the Bank of America Securities 2023 Healthcare ConferenceGlobeNewsWire • 05/04/23
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/17/23
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/13/23
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/23/23
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific ConferenceGlobeNewsWire • 03/22/23
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific ConferenceGlobeNewsWire • 03/13/23
PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 02/27/23